Brind.

OCS is seeking Priority Medicines and Breakthrough Therapy designations for Privosegtor for optic neuritis from the FDA and EMA.

Steady: 0 in the last 7 days Updated oct 29

The latest in this situation

  1. Positive ACUITY findings supported FDA and EMA designation for OCS's drug.

How it started

2 reports, 1 independent, last reported Jul 2. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

OCS is seeking Priority Medicines and Breakthrough Therapy designations for Privosegtor for optic neuritis from the FDA and EMA.

Who's involved

What this event is mainly about
OCSFDAEuropean Medicines Agency

How it developed

Newest first. Tap a step to see who reported it.
  1. Positive ACUITY findings supported FDA and EMA designation for OCS's drug.Sub-event
  2. Privosegtor seeks regulatory designations (PM/BTD) from FDA and EMA for optic neuritis.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story